Dr. Tom Van Der Hulle

This study looks at whether taking cabozantinib less often (skipping doses) works just as well as the usual way of lowering the dose for people with advanced kidney cancer. About 34 adults who are already on a stable dose will try both methods for 4 weeks each. Researchers will c…